Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence.
clinical guidelines
patient experiences
rheumatoid arthritis
Journal
Musculoskeletal care
ISSN: 1557-0681
Titre abrégé: Musculoskeletal Care
Pays: England
ID NLM: 101181344
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
14
03
2019
revised:
10
04
2019
accepted:
13
04
2019
pubmed:
31
5
2019
medline:
15
8
2020
entrez:
1
6
2019
Statut:
ppublish
Résumé
Biologic therapies have increased the control of disease activity in rheumatoid arthritis (RA). Questions remain about tapering biologics when remission is achieved in RA. The patient perspective has to be incorporated in pragmatic applications of tapering but is rarely accounted for in clinical studies of tapering. The aim of the present review was to summarize the evidence about RA patient perspectives on biologic tapering. We provided a narrative summary of the currently small body of research on patient perspectives retrieved through systematic searches with an emphasis on seeking qualitative research. In addition, we provided an update on relevant clinical research and financial considerations that frame the findings on patient perspectives. Financial considerations around commencing/continuing on biologic therapies in RA vary internationally and have implications for patient perspectives. Recent clinical studies indicate that the benefit of tapering biologic therapy when in remission are predicted by drug concentration and aspects of disease activity, severity and duration. Three major concerns have been identified from studies of patient perspectives on biologic tapering: (a) disease relapse; (b) access to treatment in the case of disease flare when tapering; and (c) local motivation for dose reduction (i.e., driven by funding or health benefit). More research is needed on tapering biologics, and should include studies of patient perspectives as well as health economic evaluations. Patient decision aids are a potential way of applying clinical and patient-focused evidence to help all parties come to a decision, but require developmental research and pragmatic evaluation.
Substances chimiques
Antirheumatic Agents
0
Biological Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
161-169Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Aletaha, D., Snedecor, S. J., Ektare, V., Xue, M., Bao, Y., & Garg, V. (2017). Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. ClinicoEconomics and Outcomes Research, 9, 451-458. https://doi.org/10.2147/CEOR.S136327
Arthritis Consumer Experts. (2018). Arthritis Medications Report Card. Where does your province rank? Retrieved from http://jointhealth.org/programs-jhreportcard.cfm?locale=en-CA
Bansback, N., Li, L., Lynd, L., & Bryan, S. (2014). Development and preliminary user testing of the DCIDA (Dynamic computer interactive decision application) for ‘nudging’ patients towards high quality decisions. BMC Medical Informatics and Decision Making, 14(62). https://doi.org/10.1186/1472-6947-14-62
Bergstra, S., Branco, J., Vega-Morales, D., Salomon-Escoto, K., Govind, N., Allaart, C., & Landewé, R. (2018). Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: Results from the METEOR-registry. Annals of the Rheumatic Diseases, 77, 1413-1420. https://doi.org/10.1136/annrheumdis-2018-213289
Bouman, C. A., van Herwaarden, N., van den Hoogen, F. H., van der Maas, A., van den Bemt, B. J., & den Broeder, A. A. (2017). Prediction of successful dose reduction or discontinuation of adalimumab, etanercept or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement. Expert Opinion on Drug Metabolism & Toxicology, 3, 597-604. https://doi.org/10.1080/17425255.2017.1320390
Bridges, S., White, D., Worthing, A., Gravallese, E., O'Dell, J., Nola, K., … American College of Rheumatology (2018). The science behind biosimilars: Entering a new era of biologic therapy. Arthritis and Rheumatology, 70(3), 334-344. https://doi.org/10.1002/art.40388
Fautrel, B., Pham, T., Alfaiate, T., Gandjbakhch, F., Foltz, V., Morel, J., … Tubach, F. (2016). Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: Results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study). Annals of the Rheumatic Diseases, 75, 59-67. https://doi.org/10.1136/annrheumdis-2014-206696
Fraenkel, L., Matzko, C. K., Webb, D. E., Oppermann, B., Charpentier, P., Peters, E., … Newman, E. D. (2015b). Use of decision support for improved knowledge, values clarification, and informed choice in patients with rheumatoid arthritis. Arthritis Care & Research, 67, 1496-1502. https://doi.org/10.1002/acr.22659
Fraenkel, L., Peters, E., Charpentier, P., Olsen, B., Errante, L., Schoen, R. T., & Reyna, V. (2012). Decision tool to improve the quality of care in rheumatoid arthritis. Arthritis Care & Research, 64, 977-985. https://doi.org/10.1002/acr.21657
Fraenkel, L., Seng, E. K., Cunningham, M., & Mattocks, K. (2015a). Understanding how patients (vs physicians) approach the decision to escalate treatment: A proposed conceptual model. Rheumatology, 54, 278-285. https://doi.org/10.1093/rheumatology/keu324
Fraenkel, L., Street, R. L., & Fried, T. R. (2011). Development of a tool to improve the quality of decision making in atrial fibrillation. BMC Medical Informatics and Decision Making, 11, 59. https://doi.org/10.1186/1472-6947-11-59
Hale, E. D., Treharne, G. J., & Kitas, G. D. (2007). The Common-Sense Model of self-regulation of health and illness: How can we use it to understand and respond to our patients' needs? Rheumatology, 46, 904-906. https://doi.org/10.1093/rheumatology/kem060
Haschka, J., Englbrecht, M., Hueber, A., Manger, B., Kleyer, A., Reiser, M., … Fleck, M. (2016). Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: Interim results from the prospective randomised controlled RETRO study. Annals of the Rheumatic Diseases, 75, 45-51. https://doi.org/10.1136/annrheumdis-2014-206439
Henaux, S., Ruyssen-Witrand, A., Cantagrel, A., Barnetche, T., Fautrel, B., Filippi, N., … Constantin, A. (2018). Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: Systematic analysis of the literature and metaanalysis. Annals of the Rheumatic Diseases, 77, 515-522. https://doi.org/10.1136/annrheumdis-2017-212423
Hewlett, S., Haig-Ferguson, A., Rose-Parfitt, E., Halls, S., Freke, S., & Creamer, P. (2018). Dose reduction of biologic therapy in inflammatory arthritis: A qualitative study of patients' perceptions and needs. Musculoskeletal Care, 17, 63-71. https://doi.org/10.1002/msc.1367
Holmes, C., Wallis, D., Holroyd, C., Sonpal, K., Zarroug, J., Adams, J., & Edwards, C. A.-H. (2018). Tapering biological therapies: What do patients think? Rheumatology, 57(Suppl. 3), 494. https://doi.org/10.1093/rheumatology/key075.494
Hopkins, A., Proudman, S., Vitry, A., Sorich, M., Cleland, L., & Wiese, M. (2016). Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. Medical Journal of Australia, 204, 64-68. https://doi.org/10.5694/mja15.00716
Jones, C., Robinson, H., Rees, D., Jolliffe, V., Trickey, J., Wood, J., … Peall, A. (2017). A patient satisfaction survey: Patients' perceptions of biologic dose tapering. Annals of the Rheumatic Diseases, 76(Suppl. 2), 1514. https://doi.org/10.1136/annrheumdis-2017-eular.1862
Kaneko, Y., Kato, M., Tanaka, Y., Inoo, M., Kobayashi-Haraoka, H., Amano, K., … Tanaka, E. (2018). Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: Results from a prospective randomised controlled study (the second year of the SURPRISE study). Annals of the Rheumatic Diseases, 77, 1268-1275. https://doi.org/10.1136/annrheumdis-2018-213416
Kievit, W., van Herwaarden, N., van den Hoogen, F., van Vollenhoven, R., Bijlsma, J., van den Bemt, B., … den Broeder, A. (2017). Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: Analyses of the DRESS study. Annals of the Rheumatic Diseases, 75, 1939-1944. https://doi.org/10.1136/annrheumdis-2015-208317
Laires, P., Exposto, F., Mesquita, R., Martins, A., Cunha-Miranda, L., & Fonseca, J. (2013). Patients' access to biologics in rheumatoid arthritis: A comparison between Portugal and other European countries. European Journal of Health Economics, 14, 875-885. https://doi.org/10.1007/s10198-012-0432-5
l'Ami, M., Krieckaert, C., Nurmohamed, M., van Vollenhoven, R. F., Rispens, T., Boers, M., & Wolbink, G. (2018). Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: An open-label, non-inferiority, randomised clinical trial. Annals of the Rheumatic Diseases, 77, 484-487. https://doi.org/10.1136/annrheumdis-2017-211781
Lau, C., Chia, F., Harrison, A., Hsieh, T., Jain, R., Jung, S., … Yeap, S. (2015). APLAR rheumatoid arthritis treatment recommendations. International Journal of Rheumatic Diseases, 18, 685-673. https://doi.org/10.1007/s10198-012-0432-5
Li, L. C., Shaw, C. D., Lacaille, D., Yacyshyn, E., Jones, C. A., Koehn, C., … Bansback, N. (2018). Effects of a web-based patient decision aid on biologic and small-molecule agents for rheumatoid arthritis: Results from a proof-of-concept study. Arthritis Care and Research, 70, 343-352. https://doi.org/10.1002/acr.23287
López-González, R., León, L., Loza, E., Redondo, M., Garcia de Yebenes, M., & Carmona, L. (2015). Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: A systematic literature review. Clinical and Experimental Rheumatology, 33, 559-569. http://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=25602291
Naredo, E., Valor, L., De la Torre, I., Montoro, M., Bello, N., Martínez-Barrio, J., … González, C. M. (2015). Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis. Rheumatology, 54, 1408-1414. https://doi.org/10.1093/rheumatology/kev006
National Institute for Health and Care Excellence. (2016). Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal guidance [TA375]. London: National Institute for Health and Care Excellence. Retrieved from https://www.nice.org.uk/guidance/TA375
O'Connor, A., Tugwell, P., Wells, G., Elmslie, T., Jolly, E., Hollingworth, G., … Mackenzie, T. (1998). Randomized trial of a portable, self-administered decision aid for post-menopausal women considering long-term preventive hormone therapy. Medical Decision Making, 18, 295-303. https://doi.org/10.1177/0272989X9801800307
Pharmaceutical Management Agency. (2017). Top 20 medicines by cost. Wellington: PHARMAC. Retrieved from https://www.pharmac.govt.nz/about/2016/top-20-by-cost/
Pharmaceutical Management Agency. (2018). Adalimumab special authority criteria. Wellington: PHARMAC. Retrieved from https://www.pharmac.govt.nz/2018/08/01/SA1621.pdf
Rothery, C., Bojke, L., Richardson, G., Bojke, C., Moverley, A., Coates, L., … Helliwell, P. (2016). A discrete choice experiment to explore patients' willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. Clinical Rheumatology, 35, 1967-1974. https://doi.org/10.1007/s10067-016-3452-1
Singh, J., Cameron, C., Noorbaloochi, S., Cullis, T., Tucker, M., Christensen, R., … Wells, G. (2015a). Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis. Lancet, 386, 258-265. https://doi.org/10.1016/S0140-6736(14)61704-9
Singh, J., Saag, K., Bridges, S. Jr., Akl, E., Bannuru, R., Sullivan, M., … McAlindon, T. (2015b). 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis and Rheumatism, 68, 1-26. https://doi.org/10.1002/art.39480
Smolen, J., Nash, P., Durez, P., Hall, S., Ilivanova, E., Irazoque-Palazuelos, F., … Vlahos, B. (2013). Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. Lancet, 381, 918-929. https://doi.org/10.1016/S0140-6736(12)61811-X
Smolen, J., Szumski, A., Koenig, A., Jones, T., & Marshall, L. (2018). Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: Results of the PRESERVE trial. Arthritis Research & Therapy, 20(1), 8. https://doi.org/10.1186/s13075-017-1484-9
Smolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., … van der Heijde, D. (2017). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76, 960-977. https://doi.org/10.1136/annrheumdis-2016-210715
Stacey, D., Legare, F., Lewis, K., Barry, M., Bennett, C., Eden, K., … Trevena, L. (2017). Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews, 4, CD001431. https://doi.org/10.1002/14651858.CD001431.pub4
Tanaka, Y., Hirata, S., Kubo, S., Fukuyo, S., Hanami, K., Sawamukai, N., … Sawamura, F. (2015). Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Annals of the Rheumatic Diseases, 74(2), 389-395. https://doi.org/10.1136/annrheumdis-2013-204016
Treharne, G. J., Lyons, A. C., Hale, E. D., Douglas, K. M. J., & Kitas, G. D. (2006). ‘Compliance’ is futile but is ‘concordance’ between rheumatology patients and health professionals attainable? Rheumatology, 45(1), 1-5. https://doi.org/10.1093/rheumatology/kei223
Tweehuysen, L., van den Ende, C. H., Beeren, F. M., Been, E. M., van den Hoogen, F. H., & den Broeder, A. A. (2016). Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: A systematic review. Arthritis and Rheumatology, 69(2), 301-308. https://doi.org/10.1002/art.39946
van Herwaarden, N., den Broeder, A. A., Jacobs, W., van der Maas, A., Bijlsma, J. W. J., & van Vollenhoven, R. F. (2014). Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database of Systematic Reviews, 9, CD010455. https://doi.org/10.1002/14651858.CD010455.pub2
van Herwaarden, N., van der Maas, A., Minten, M. J., van den Hoogen, F., Kievit, W., van Vollenhoven, R., … den Broeder, A. (2015). Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: Open label, randomised controlled, non-inferiority trial. BMJ, 350, h1389. https://doi.org/10.1136/bmj.h1389
Vanier, A., Mariette, X., Tubach, F., Fautrel, B., & the STRASS Study Group (2017). Cost-effectiveness of TNF-blocker injection spacing for patients with established rheumatoid arthritis in remission: An economic evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial. Value in Health, 20(4), 577-585. https://doi.org/10.1016/j.jval.2017.01.005
Verhoef, L., Selten, E., Vriezekolk, J., de Jong, A., van den Hoogen, F., den Broeder, A., & Hulscher, M. (2018). The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: A mixed methods study. Rheumatology, 57, 1947-1955. https://doi.org/10.1093/rheumatology/key205
Vogelzang, E., Hebing, R., Nurmohamed, M., van Kuijk, A., Kruijff, J., l'Ami, M., … Wolbink, G. (2018). Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up. PLoS ONE, 13, e0205125. https://doi.org/10.1371/journal.pone.0205125
Wallis, D., Holroyd, C., Sonpal, K., Zarroug, J., Adams, J., & Edwards, C. A.-H. (2016). Dose reduction of biological therapies in rheumatoid arthritis - The patient's perspective. Annals of the Rheumatic Diseases, 75(Suppl. 2), 1313. https://doi.org/10.1136/annrheumdis-2016-eular.1475
Wolfe, F., & Michaud, K. (2007). Resistance of rheumatoid arthritis patients to changing therapy discordance between disease activity and patients' treatment choices. Arthritis and Rheumatism, 56, 2135-2142. https://doi.org/10.1002/art.22719
Yamanaka, H., Nagaoka, S., Lee, S., Bae, S.-C., Kasama, T., Kobayashi, H., … ENCOURAGE Study Group (2016). Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-Results from the ENCOURAGE study, a prospective, international, multicenter randomized study. Modern Rheumatology, 26, 651-661. https://doi.org/10.3109/14397595.2015.1123349